healthandpharma7d
First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Adults with Obesity
The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea in adults with ...
healthandpharma8d
FDA Approves BRAFTOVI Combination as First-Line Treatment for BRAF V600E–Mutant Colorectal Cancer
The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant ...
healthandpharma9d
The Recombinant Polyclonal Drug Candidate GIGA-2339 for Hepatitis B Treatment
We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the ...
healthandpharma12d
How Qvin's Q-Pad Could Transform Women’s Health Through Menstrual Blood Testing
Today, we are honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we will explore the groundbreaking Q-Pad technology, the ...
healthandpharma14d
AbbVie Acquires Nimble in $200 Million Deal to Strengthen Immunology Pipeline
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...
healthandpharma14d
Palbociclib Combination Yields PFS Improvement in HR+, HER2+ Breast Cancer
The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...
healthandpharma15d
Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
healthandpharma16d
NATALEE Trial: Ribociclib Shows Promising Long-Term Benefits in Early Breast Cancer Treatment
Kisqali (ribociclib) combined with endocrine therapy demonstrates a sustained 28.5% reduction in distant recurrence for ...